UroGen Pharma Q1 2025: $100M Assets, $8.8M Net Loss
Ticker: URGN · Form: 10-Q · Filed: May 12, 2025 · CIK: 1668243
| Field | Detail |
|---|---|
| Company | Urogen Pharma Ltd. (URGN) |
| Form Type | 10-Q |
| Filed Date | May 12, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, quarterly-report
TL;DR
UroGen Pharma Q1 2025: $100M assets, $46.1M liabilities, $8.8M loss. Revenue $0.8M.
AI Summary
UroGen Pharma Ltd. filed its Q1 2025 10-Q report on May 12, 2025, for the period ending March 31, 2025. The company reported total assets of $100 million and total liabilities of $46.1 million, resulting in total equity of $42.2 million. Revenue for the quarter was $0.8 million, with a net loss of $8.8 million.
Why It Matters
This filing provides a snapshot of UroGen Pharma's financial health and operational performance for the first quarter of 2025, crucial for investors assessing the company's stability and growth prospects.
Risk Assessment
Risk Level: medium — The company reported a net loss, indicating ongoing operational costs exceeding revenue, which can pose a risk to financial stability if not managed effectively.
Key Numbers
- $100.0B — Total Assets (Represents the company's total resources as of March 31, 2025.)
- $46.1B — Total Liabilities (Indicates the company's total obligations as of March 31, 2025.)
- $42.2B — Total Equity (Shows the net worth of the company after deducting liabilities from assets.)
- $0.8M — Revenue (Represents the income generated from the company's operations in Q1 2025.)
- $8.8M — Net Loss (Indicates the company's profitability, showing a loss of $8.8 million for the quarter.)
Key Players & Entities
- UroGen Pharma Ltd. (company) — Filer of the 10-Q report
- 20250331 (date) — End of the reporting period
- 20250512 (date) — Filing date of the report
- $100,000,000 (dollar_amount) — Total assets
- $46,101,785 (dollar_amount) — Total liabilities
- $42,231,746 (dollar_amount) — Total equity
- $806,222 (dollar_amount) — Revenue for the period
- $8,803,000 (dollar_amount) — Net loss for the period
FAQ
What were UroGen Pharma's total assets as of March 31, 2025?
UroGen Pharma's total assets were $100,000,000 as of March 31, 2025.
What was the company's net loss for the first quarter of 2025?
The company reported a net loss of $8,803,000 for the first quarter of 2025.
What was the reported revenue for the period ending March 31, 2025?
Revenue for the period ending March 31, 2025, was $806,222.
What were UroGen Pharma's total liabilities as of March 31, 2025?
Total liabilities for UroGen Pharma were $46,101,785 as of March 31, 2025.
When was this 10-Q filing submitted to the SEC?
This 10-Q filing was submitted to the SEC on May 12, 2025.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding UroGen Pharma Ltd. (URGN).